Marc Lichtenfeld, Wealthy Retirement, Author at Daily Trade Alert

This Biotech’s 4%-Plus Dividend is ‘Moderately Safe’

Declining cash flow over the past few years lowers its Safety Rating, but I suspect we’ll see an upgrade to a lower risk rating next year.

In short, stochastic are very oversold and starting to turn higher.

No other sector has such important catalysts that can instantly revalue a company.

If history is any indication, the company likely won’t be able to sustain strong enough positive cash flows to continue paying its big dividend.

They are a great way to get some income today and an even larger “paycheck” for your heirs later.